• Majority of cancer biopsies from CNS tumors, including recurrent GBM, have been shown to over-express the IL4R with little or no expression in normal adult and pediatric brain tissue
  • MGMT positive cancer cells are resistant to temozolomide but are sensitive to MDNA55. MDNA55 could be an alternative for GBM patients who are not likely to benefit from the current standard of care
  • GBM has a robust immunosuppressive tumor micro-environment (TME) and comprises ~40% of the tumor mass. The IL4R is up-regulated on glioma-infiltrating myeloid derived suppressor cells (MDSCs) but not in the periphery or in normal brain. Purging MDSCs with MDNA55 may alleviate the immune block associated with GBM thereby promoting anti-tumor immunity and long-term disease control
  • MDNA55’s cell-killing ability is not growth-rate dependent. Quiescent cancer stem cells (CSCs) and slower growing cells of the TME are as sensitive to MDNA55 as rapidly dividing tumor cells
  • Furin-like proteases are required for intracellular activation of MDNA55. High expression levels of furin in glioma cells as opposed to normal cells provides additional tumor specificity
  • MDNA55 is effective against hypoxic cells in the tumor inner core that often become resistant to radiation and chemotherapeutic drugs, a phenomenon common to tumors of the CNS
  • In order to by-pass the blood brain barrier (BBB), MDNA55 is administered locally by intratumoral infusion using Convection Enhanced Delivery (CED). This approach maximizes tumor exposure following a single infusion while limiting systemic toxicity. Since tumors typically recur within 2cm of the initial occurrence, intra- and peri-tumoral infusion would benefit patients without the need to first resect the tumor